Nitrofurantoin or Fosfomycin: The better choice for lower urinary tract infection?
DOI:
https://doi.org/10.53685/jshmdc.v7i1.382Keywords:
Nitrofurantoin, Fosfomycin, urinary tract infection, clinical and microbiologic responseAbstract
Background: Almost 50%-60% of women have at least one episode of urinary tract infection (UTI) during their lifetime.
Objective: To determine and compare the effectiveness of oral Fosfomycin and nitrofurantoin in women of reproductive age with lower UTIs.
Methods: A quasi-experimental study was conducted in the urogynaecology department of Shalamar Hospital, Lahore, Pakistan, from 4th September 2024 to 4th March 2025. A total of 392 females presenting with symptoms of lower urinary tract infection were included. Participants received empirical treatment with either nitrofurantoin (Group A) or Fosfomycin (Group B) orally after providing a baseline urine sample for culture and sensitivity testing. The primary outcome was the assessment of clinical resolution at the first follow-up visit on day 7. The second follow-up visit on day 14 was conducted to assess bacterial eradication. Data were analyzed using SPSS version 21.
Results: Nitrofurantoin use was associated with higher clinical improvement (82% vs. 71%, p=0.016) and bacteriological resolution (91% vs. 84%, p=0.020) compared with Fosfomycin. Diarrhea was the predominant adverse effect reported more frequently with Fosfomycin use (12.7% vs 6.1%, p=0.02). Nitrofurantoin users achieved faster recovery of symptoms when compared with Fosfomycin e.g., dysuria relief in 2.4 vs 3.1 days (p=0.003), urinary frequency decreased in 3.1 vs 4 days (p=0.005), suprapubic pain settled in 2.9 vs 3.5 days (p=0.04), better post-treatment quality of life in 8.8 vs 8.2 days (p=0.009), and greater willingness to reuse the drug in 89% vs 78% (p=0.008).
Conclusion: Nitrofurantoin demonstrated superior clinical and bacteriological efficacy over Fosfomycin, with faster symptom resolution and greater patient satisfaction, supporting its use as the preferred first-line agent for uncomplicated lower UTIs. Fosfomycin remains a viable alternative where adherence is a concern.
.
References
Al Lawati H, Blair BM, Larnard J. Urinary tract infections: Core curriculum. Am J Kidney Dis. 2023;83(1):90-100.
World Health Organization. Global Antimicrobial Resistance Surveillance System (GLASS) report: Early implementation 2017–2018. Geneva (Switzerland): WHO; 2019.
Bullens M, de Cerqueira Melo A, Raziq S, Lee J, Khalid GG, Khan SN, et al. Antibiotic resistance in patients with urinary tract infections in Pakistan. Public Health Action. 2022;12(1):48-52.
Shaheen G, Rahman SU, Malik S, Akhtar M, Khan HUR, Khan AH.Antibiotic sensitivity and resistance patterns in complicated urinary tract infections. Pakistan Journal of Medical & Health Sciences. 2023;17(11):462.
Hussain A, Sohail M, Abbas Z. Prevalence of Enterococcus faecalis mediated UTI and its current antimicrobial susceptibility pattern in Lahore, Pakistan. J Pak Med Assoc. 2016; 66:1232-1236.
Sharma S, Verma PK, Rawat V, Varshney U, Singh RK. Fosfomycin versus nitrofurantoin for the treatment of lower UTI in outpatients. J Lab Physicians. 2021; 13:118-122.
Advani SD, North R, Turner NA, Ahmadi S, Denniss J, Francis A, et al. Performance of urinalysis parameters in predicting urinary tract infection. Clin Infect Dis. 2023;79(3):600–603.
Gupta T, Chavan S, Raut SS.Nitrofurantoin susceptibility pattern in uropathogens: a comparative analysis of antimicrobial resistance. Int J Sci Res. 2024;13(1):60–63.
Stamm WE. Criteria for the diagnosis of urinary tract infection and for the assessment of therapeutic effectiveness. Infection.1992May;20(S3):S151–S154.
O’Horo JC, Tande A. 5-day nitrofurantoin increased clinical resolution of uncomplicated UTIs in women vs 1-dose Fosfomycin. Ann Intern Med. 2018;169(4).
Tahir HB, Khan MNA, Khan R, Tariq R, Ahmed B, Khan HW. Efficacy of five-days nitrofurantoin therapy versus Fosfomycin stat dose in clinical resolution of uncomplicated urinary tract infections. Pak Armed Forces Med J. 2023;73(1):42-45.
Nicolle LE. Uncomplicated urinary tract infection in adults including uncomplicated pyelonephritis. Urol Clin North Am. 2008;35(1):1-12.
Ankita D, Grover P, Arora B, Jain D, Chugh S. Efficacy of nitrofurantoin and Fosfomycin against extended spectrum beta-lactamase producing uropathogens in the era of antibiotic resistance: A cross-sectional study. Asian J Med Health.2024;22(8):65-71.
Azad MD, Kumari S, Jha K, Naresh RS. Resurgence of nitrofurantoin and Fosfomycin as effective oral empirical treatment options for multidrug resistant uropathogens. Int J Acad Med Pharm. 2024;6(4):616-621.
Jain R, Pal N, Hooja S. Fosfomycin susceptibility among multidrug resistant and extended spectrum β-lactamase producing uropathogenic Escherichia coli isolates at a tertiary care hospital of Western India. CHRISMED J Health Res. 2022; 9:125-129.
Ten Doesschate T, van Haren E, Wijma RA, Koch BCP, Bonten MJM, van Werkhoven CH. The effectiveness of nitrofurantoin, Fosfomycin and trimethoprim for the treatment of cystitis in relation to renal function. Clin Microbiol Infect. 2020; 26:1355-1360.
Konwar M, Gogtay NJ, Ravi R, Thatte UM, Bose D. Evaluation of efficacy and safety of Fosfomycin versus nitrofurantoin for the treatment of uncomplicated lower urinary tract infection (UTI) in women—A systematic review and meta-analysis. J Chemother. 2022; 34:139-148.
Daneman N, Chateau D, Dahl M, Zhang J, Fisher A, Sketris I, et al. Fluoroquinolone use for uncomplicated urinary tract infections in women: A retrospective cohort study. Clin Microbiol Infect. 2020; 26:613-618.
Huttner A, Kowalczyk A, Turjeman A, Babich T, Brossier C, Eliakim-Raz N, et al. Effect of 5-day nitrofurantoin vs. single-dose Fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: A randomized clinical trial. JAMA. 2018; 319:1781-1789.
Verma T, Manhas GS, Manhas RS. Efficacy and Safety of Single-dose Fosfomycin for Uncomplicated Urinary Tract Infection in Women: Systematic Review and Meta-analysis. Journal of Mid-life Health. 2025 Apr 1;16(2):124-36.
Shafrir A, Oster Y, Shauly-Aharonov M, Strahilevitz J. Real-life comparison of Fosfomycin to nitrofurantoin for the treatment of uncomplicated lower urinary tract infection in women. Biomedicines. 2023; 11:1019.
Anita K, Razdan Kaul A, Dhanesha G, Priyambada U. Comparative efficacy and safety of Fosfomycin and nitrofurantoin in acute uncomplicated lower urinary tract infection in young women: A randomized, open label, comparative study. Indian J Gynecol. 2019;1(1):101.
Chouhan D, Dodwa DS, Sisodiya DK. Efficacy and safety of nitrofurantoin and Fosfomycin in UTI. Azerbaijan Pharm Pharmother J. 2024;23(4):55-60.
Kornfält Isberg H, Hedin K, Melander E, Mölstad S, Beckman A. Uncomplicated urinary tract infection in primary health care: Presentation and clinical outcome. Infect Dis. 2021; 53:94-101.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Sheema Yousuf, Nazli Hameed
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
-
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
-
Non Commercial — You may not use the material for commercial purposes.
-
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
This work is licensed under a 
